Summary
Regeneron Pharmaceuticals, Inc. (REGN) has entered into a significant non-exclusive license agreement with Astellas Pharma Inc. This deal grants Astellas rights to utilize Regeneron's proprietary VelocImmune® technology for the discovery of human monoclonal antibodies. The agreement provides Regeneron with immediate financial benefits and potential future revenue streams, positioning the company's innovative technology as a valuable asset in the pharmaceutical industry.
Key Highlights
- 1Regeneron entered into a non-exclusive license agreement with Astellas Pharma Inc. on March 30, 2007.
- 2The agreement grants Astellas rights to use Regeneron's VelocImmune® technology for discovering human monoclonal antibodies.
- 3Regeneron received a $20 million upfront payment from Astellas.
- 4Astellas may make up to five additional annual payments of $20 million each, subject to certain conditions including termination rights.
- 5Regeneron is eligible for mid-single-digit royalties on future sales of antibody products developed by Astellas using the VelocImmune® technology.
- 6This agreement highlights the commercial value and potential of Regeneron's VelocImmune® platform.